Beyond GLP-1: Emerging Biologic Therapies Reshaping Chronic Disease Care
Lakshmi, Editorial Team, Pharma Focus Europe
Chronic disease care is moving beyond a single drug class. Ultra-long-acting antibodies, amylin-based therapies and upstream immune blockers are changing what counts as value, while a failed cardiovascular outcomes trial shows the limits of biomarker promise. For European pharma leaders, success now depends on linking dosing interval, response quality and outcome evidence to uneven national reimbursement and a reshaped EU regulatory framework.
When GLP-1 Stopped Being the Whole Story
For most of this decade, one drug class has dominated boardroom conversations about chronic disease. Its commercial force needs no further retelling. Its deeper legacy is easier to miss: it taught health systems and patients to expect that a long-term condition could be altered by a well-engineered injection, and then forced everyone to ask what that alteration is worth.
That question has now travelled well beyond the metabolic clinic. A new generation of antibodies and related long-acting therapies is advancing through respiratory medicine, nephrology, cardiology and obesity care, and potency alone no longer settles the contest. Four measures increasingly decide value: how rarely a patient needs treatment, how good the response is, how far upstream the therapy acts, and whether a biomarker gain becomes a clinical outcome. European leaders must weigh those measures while regulatory protection is being rewritten and payer appetite varies sharply by border.
Two Injections a Year: Biologic Therapies Turn Time Into a Clinical Asset
The clearest signal came in February 2026, when the European Commission cleared depemokimab, a twice-yearly anti-IL-5 antibody, as the first ultra-long-acting biologic for respiratory disease in the EU. Its pivotal severe asthma trials recorded exacerbation reductions of 58% and 48% over 52 weeks, and a 2026 non-inferiority study provided the first evidence that patients controlled on existing IL-5 pathway agents can switch without losing that control.
Dosing frequency once sounded like a convenience claim. In chronic care it behaves more like an economic variable. Each avoided administration removes a moment when a patient can drift away from therapy and frees specialist capacity that many European systems cannot spare.
Obesity is following the same logic. Maridebart cafraglutide, an antibody-peptide conjugate that blocks the GIP receptor while activating the GLP-1 receptor, produced mean weight loss of roughly 12% to 16% at 52 weeks in phase 2 on monthly dosing, with early signs that quarterly maintenance may be possible. Its phase 3 programme includes a study of patients switching from existing GLP-1 therapy, a telling choice: the prize for interval-led biologics is partly the patient already on treatment.
There is a commercial caveat. A long half-life is also a long commitment if a patient responds poorly, and some specialists prefer to confirm response on a shorter-acting agent first. Forecasts that assume immediate first-line use of ultra-long-acting products deserve a second look.
Obesity Biologics After GLP-1: The Contest Moves to Tolerability and Muscle
The next obesity wave is not simply chasing a larger headline number. Long-acting amylin analogues act on appetite partly independently of incretin pathways, and their appeal lies in how patients experience them. In phase 2, petrelintide delivered up to 10.7% weight loss at 42 weeks, with vomiting in 3% of treated participants and only 1.5% stopping because of gastrointestinal events. Eloralintide reached a far wider range, 9.5% to 20.1% across doses at 48 weeks against 0.4% on placebo. If phase 3 confirms these profiles, persistence could become the competitive battleground, since a modest loss sustained for years may outperform a dramatic loss abandoned in months.
Body composition is the second front. Bimagrumab, a monoclonal antibody against activin type II receptors, was combined with semaglutide in a phase 2 trial in which about 93% of weight lost came from fat, compared with about 72% on semaglutide alone. For an ageing continent, that is a meaningful proposition. Whether European payers will fund muscle preservation is unresolved, and developers will need functional endpoints rather than scan data to make that case.
Vocabulary matters here too. Amylin analogues are peptides and Lp(a) silencers are oligonucleotides, not antibodies, even though they are often grouped with biologics in strategy discussions. The distinction shapes manufacturing, follow-on competition and regulatory route, so portfolio reviews should not treat "beyond GLP-1" as one modality.
Upstream of the Damage: Biologics That Chase the Cause, Not the Complication
Nephrology offers perhaps the most striking evidence of what upstream targeting can do. In IgA nephropathy, the anti-APRIL antibody sibeprenlimab reported a 24-month mean eGFR change of +1.3 mL/min/1.73 m² against -7.9 on placebo, with an annualised slope consistent with near-physiological decline. The developer has reported only topline two-year findings so far, but the implication is significant: when a therapy aims to hold kidney function steady rather than slow its loss, the value argument shifts towards the dialysis and transplant costs that may never be incurred.
Respiratory medicine shows the other side of going upstream. Tezepelumab, which blocks the epithelial cytokine TSLP, reduced asthma exacerbations regardless of baseline type 2 biomarker status, challenging the eosinophil-led selection that has guided prescribing for years. Broader eligibility is commercially attractive, yet it removes the tidy biomarker gate that payers use to contain budgets. Upstream biologics may therefore need access arguments as sophisticated as their science.
The 8,323-Patient Warning for Every Biologic Strategist
On 4 September 2026, the Lp(a)HORIZON outcomes trial delivered the field's most sobering result. Pelacarsen, an antisense therapy, lowered lipoprotein(a) in 8,323 patients with established cardiovascular disease, yet did not significantly reduce major cardiovascular events. Background risk was tightly managed, with mean LDL cholesterol near 66 mg/dL, and full data are still awaited. One siRNA candidate in the class has been dropped despite encouraging phase 2 results, while larger outcomes programmes continue, including one above 17,000 patients that is not expected to report until 2029.
Deeper reductions achieved by siRNA agents may still change the answer. The lesson for leaders reaches well beyond this one target. Strong genetic rationale and a dramatic biomarker response remain hypotheses until outcomes confirm them. Capital committed to launch infrastructure ahead of that proof should be staged accordingly, across every chronic disease programme built on a surrogate.
Europe's Uneven Door: Who Pays for Chronic Care Biologics Now
Access to today's obesity medicines previews the environment that newer entrants will face. On 15 June 2026, France became the first EU country to offer permanent standard reimbursement, at an official 65% rate, for patients with a BMI of at least 35 plus a comorbidity or a BMI of at least 40. As of June 2026, Germany, Italy and Spain offered no obesity reimbursement. In the UK, an estimated 1.5 to 1.6 million adults had used these therapies by 2025, more than 90% of them privately.
Self-pay is therefore no longer a minor side channel but part of the European market's structure, with monthly out-of-pocket costs of €136 to €400 across the four largest EU markets. A successor product must now persuade a health technology assessor and a paying consumer simultaneously, and those audiences value different things. Meanwhile, EU Joint Clinical Assessment, which already covers oncology and advanced therapies, extends to orphan medicines in 2028 and all new medicines from 2030. Any chronic biologic launching at the turn of the decade should assume comparator expectations that placebo-controlled programmes alone may not satisfy.
A Shorter Clock, a Sharper Test: Chronic Biologics Under the EU Pharma Package
The Council of the EU adopted its position on the pharma package on 28 September 2026, with the European Parliament's final step still pending. The baseline becomes eight years of data protection plus one of market protection, with conditional extensions and an overall 11-year cap. Standard EMA assessment falls from 210 to 180 days, and an expanded Bolar exemption lets biosimilar developers prepare pricing, reimbursement and tender activity before protection ends.
For chronic disease biologics, two provisions deserve particular attention. An extra year is available for a new indication showing significant clinical benefit, which makes the sequencing of follow-on indications, such as asthma into COPD, a board-level decision rather than a lifecycle afterthought. Comparative clinical trials can also contribute towards added protection. That creates an unusual alignment: the same study can strengthen exclusivity and answer the question payers are already asking. Companies should also check whether planned filings fall before the transition cut-off, because submission timing may determine which protection regime applies.
The Leadership Bet Beyond GLP-1
The next era of chronic care will not be won by the molecule with the most impressive phase 2 chart. It will favour organisations that treat interval, response quality, causal biology and outcome evidence as one integrated value case, then build that case for regulators, assessors and increasingly for patients paying their own way.
Forecasting must evolve as well, and quickly. A twice-yearly antibody changes volume assumptions, manufacturing plans and the meaning of adherence. European companies hold a real advantage if they design evidence with the continent's fragmented payers in mind from the outset. The real competitive question is no longer who can follow GLP-1, but who can prove, in terms each European system accepts, that a chronic condition has genuinely changed course.
FAQ
Are all therapies beyond GLP-1 true biologics?
No. Antibodies such as depemokimab and sibeprenlimab are biologics, while amylin analogues are peptides and Lp(a) silencers are oligonucleotides. The differences affect manufacturing and follow-on competition.
Why do dosing intervals matter so much to pharma leaders?
Longer intervals can support persistence and reduce clinic burden. They also alter volume forecasts, pricing logic and the evidence needed to justify switching.
How could the EU pharma package influence biologic development?
Once in force, it would shorten baseline protection while rewarding valuable new indications and comparative trials, bringing these decisions into earlier strategy.
Is obesity care reimbursed across Europe?
No. France has introduced restricted permanent reimbursement, the UK has conditional access alongside a large private market, and much of the continent remains largely self-funded.
Lakshmi is a science writer with a foundation in the laboratory. She earned her master's in biotechnology and trained through research internships at ICGEB (JNU) and DIPAS, DRDO, with her work appearing in the Egyptian Journal of Veterinary Sciences. Now APCRM-certified and part of the editorial team at Pharma Focus America and Pharma Focus Europe, she reports on pharmaceutical technology, research, and innovation — giving complex science a clear and confident voice for industry leaders.
